RxDoctor Payments Data

Navpreet Kaur

Family · Arcadia, CANPI 1982141511

Payments from drug & device makers

$1,010in general payments, 2019–2025

Across 42 payments — averaging $24.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$155
  • Amgen$150
  • Lilly USA, LLC$106
  • Exact Sciences$98
  • GSK$95
  • Xeris Pharmaceuticals, Inc.$95
  • plus $311 from 9 others

What the payments were for

  • Food & beverage$1,010100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,010 in reported general payments places this provider in the 70th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$105,072
Medicare patients
216
Services billed
1,849

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin56$65,973
JanuviaSitagliptin Phosphate54$64,716
OzempicSemaglutide59$62,603
EliquisApixaban37$50,703
TrulicityDulaglutide34$48,379
FarxigaDapagliflozin Propanediol21$31,996
XareltoRivaroxaban22$30,831
JanumetSitagliptin Phos/Metformin Hcl24$28,035
ProliaDenosumab11$18,102
LinzessLinaclotide13$10,422
VascepaIcosapent Ethyl19$7,564
Lyumjev Kwikpen U-200Insulin Lispro-Aabc18$7,027
Diclofenac Sodium28$3,683
SynthroidLevothyroxine Sodium35$3,248
Rosuvastatin Calcium221$2,972

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$155$62,60359 claims
PfizerEliquis$46$50,70337 claims
Lilly USA, LLCTrulicity$106$48,37934 claims
AmgenProlia$150$18,10211 claims
AbbVieLinzess, Synthroid$33$13,67048 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 10,634 family providers in California.

Other family in Arcadia

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →